Biotech Values

[DewDiligence]

FDA approves JNJ’s Akeega in BRCA+ CRPC:

https://www.prnewswire.com/news-releases/us-fda-approves-akeega-niraparib-and-abiraterone-acetate-the-first-and-only-dual-action-tablet-for-the-treatment-of-patients-with-brca-positive-metastatic-castration-resistant-prostate-cancer-301899028.html

Akeega is a fixed-dose combination of Zytiga and Zejula (the PARP inhibitor from GSK/Tesaro). JNJ’s licensed the commercial rights to Zejula in prostate cancer from Tesaro in 2016.

Akeega can be considered a lifecycle management maneuver by JNJ insofar as Zytiga will soon be off-patent.